Search
Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10799ApprovedInvestigationalThe vaccine contains *N. meningitis* serogroup c capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from Corynebacterium diphtheriae
Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10800ApprovedInvestigationalcapsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria meningitidis* serogroup W- … The vaccine contains* N. meningitis* serogroup y capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from Corynebacterium diphtheriae
Pramiracetam
go.drugbank.com/drugs/DB13247ApprovedPramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression [L5470].
Teicoplanin
go.drugbank.com/drugs/DB06149ApprovedInvestigationalWithdrawnAll teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.
Products: TEICOPLANINA MYLAN GENERICSN-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
go.drugbank.com/drugs/DB06944ExperimentalThis compound belongs to the naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
QR-334
go.drugbank.com/drugs/DB05473ExperimentalNo pharmaceutical interventions currently exist to treat sialorrhea.
Clomocycline
go.drugbank.com/drugs/DB00453ExperimentalClomocycline is a tetracycline used to treat bacterial infections.
QS-21
go.drugbank.com/drugs/DB05400InvestigationalQS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment
Inolimomab
go.drugbank.com/drugs/DB15628InvestigationalInolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. … It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.[A241385]
PRLX 93936
go.drugbank.com/drugs/DB06098InvestigationalPRLX 93936 is selectively toxic to cancer cells.